Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT04139434 | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML | completed | Phase 1 | 32 | Newave Pharmaceutical IncINDUSTRY | 2 | Jan 23, 2026 |
| clinicaltrials |
| NCT02862652 | Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children.(THROMBLEUKEMIA) | completed | N/A | 24 | CHU de ReimsOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05275543 | Robot Rehab: AAI With Robot During Inpatient Pediatric Rehab | completed | N/A | 25 | University of NebraskaOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06068621 | Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06286332 | Music Therapy in Acute Leukemia Patients With Fatigue | completed | N/A | 60 | Chang Gung UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05063591 | Removing Transfusion Dependence as a Barrier to Hospice Enrollment(BRUOG-407) | completed | N/A | 18 | Adam OlszewskiOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05466994 | A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03414775 | Influences of High-fiber, Organic Whole-food Formula on the Gut Microbiome in Critically Ill Children | completed | N/A | 32 | University of PittsburghOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04220684 | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | completed | Phase 1 | 19 | Sumithira VasuOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03042689 | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03904134 | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)(BMT CTN 1702) | completed | N/A | 1,753 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03594149 | Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients(AZABAC) | completed | Phase 3 | 60 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03959007 | Impact of Supportive Care on the Experience of Hospitalization of Patients Staying in the Protected Area of the Department of Blood Diseases(ASTERIA) | completed | N/A | 70 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04679285 | Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia(FERTILAM) | completed | — | 9 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05120570 | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | completed | Phase 1 / Phase 2 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04913038 | Validation of the ANI in Perpubescent Patients in Pediatric Intensive Care Unit.(ANI-EP) | completed | — | 50 | University Hospital, LilleOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05115630 | Off-the-shelf NK Cells + SCT for Myeloid Malignancies | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | completed | Phase 3 | 1,023 | Goethe UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06030089 | Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven(VENETACIBLE) | completed | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04191187 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT01869114 | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | completed | Phase 2 | 57 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT05923112 | BESPONSA Injection 1 mg Special Investigation | completed | — | 421 | PfizerINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03898128 | ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate(INO-CD22) | completed | — | 84 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05687032 | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 4 | 44 | PfizerINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice(VYSION) | completed | — | 113 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02684162 | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | completed | Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06244147 | Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults | completed | — | 200 | SF Research Institute, Inc.NETWORK | 1 | Nov 6, 2025 | clinicaltrials |
| NCT07203885 | AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment(LEAP) | completed | N/A | 10 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04188678 | Resiliency in Older Adults Undergoing Bone Marrow Transplant(REBOUND) | completed | — | 126 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT02879643 | Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy | completed | Phase 1 | 29 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 22, 2025 | clinicaltrials |
| NCT00136435 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 20, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
| NCT03118466 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 41 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03515512 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03480438 | Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab(EWALL-BOLD) | completed | Phase 2 | 52 | Goethe UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04609826 | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)(DHODH) | completed | Phase 1 | 153 | Janssen Research & Development, LLCINDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT02356159 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04984356 | A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | completed | Phase 1 | 28 | Allotera TherapeuticsINDUSTRY | 4 | Sep 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 26, 2026source: clinicaltrials